bit.bio discovery announced today that Tilmann Burckstummer has been appointed as the new Chief Executive Officer of the company. Tilmann steps up from his current role as Chief Scientific Officer and will assume responsibilities on January 17. Thomas Moser, former Chief Executive Officer, will continue serving bit.bio discovery as Chief Financial Officer and Chief Operating Officer.
Tilmann Bürckstümmer is a seasoned biotech professional who held key roles at Haplogen and Horizon Discovery. In 2018, he co-founded Myllia Biotechnology, where he led the development of a technology platform that has formed the basis for Myllia’s commercial success. Tilmann has been with bit.bio discovery since its inception in 2020 and has played a key role in the company’s success to date. He has a deep knowledge of the biotech industry and a keen understanding of the challenges and opportunities facing bit.bio discovery.
“We are delighted to have Tilmann in this new role. His experience will be instrumental in driving the growth and long-term success of bit.bio discovery's business“, says Mark Kotter, CEO of bit.bio and board member of bit.bio discovery.
“CRISPR screens have become the primary discovery engine in modern biology, but the quality of the screens is a function of the quality of the cells. Using physiologically relevant stem cell-derived models will empower the discovery of novel drug targets that have a higher chance of delivering drugs in future”, says Tilmann Burckstummer.
“I am grateful to Thomas Moser for his contributions, and we will continue to work closely together during this exciting new phase for bit.bio discovery. His experience is invaluable” , says Tilmann Burckstuemmer.
bit.bio discovery combines unbiased functional genomic screening with the best human cellular models available, to identify critical genes and pathways driving disease states or provide unique insights into the mechanism of action of drugs. It utilizes stem cells and stem cell-derived cells for the discovery of novel drug targets.